{"id":"W2987552010","doi":"10.1182/blood-2019-128404","title":"ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology","funders":"","keywords":"Medicine; Internal medicine; Chlorambucil; Gastroenterology; Clinical endpoint; Neutropenia; Obinutuzumab; Phases of clinical research; Adverse effect; Chronic lymphocytic leukemia; Pharmacology; Clinical trial; Leukemia; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00127017,0.001456224,0.00175338,0.0004707748,0.0003938939,0.001151181,0.001011762,0.001058915,0.006197758],"category_scores_gemma":[0.0008031402,0.000528141,0.001482529,0.0005038854,0.000959133,0.001070066,0.0005542741,0.003484679,0.001123576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009487903,"about_ca_system_score_gemma":0.001752227,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001139731,"about_ca_topic_score_gemma":0.003469128,"domain_scores_codex":[0.9996786,0.0001414966,0.00001513942,0.00005457168,0.00003042892,0.00007980193],"domain_scores_gemma":[0.9993135,0.00009935242,0.000130462,0.00004625766,0.00003231135,0.0003781763],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8840406,0.03622332,0.003102272,0.0007011155,0.0008230907,0.0001367082,0.000176722,0.001366591,0.0154287,0.0003168376,0.003224241,0.05445981],"study_design_scores_gemma":[0.712302,0.2771345,0.005156014,0.00003590078,0.0004456219,0.0001598292,0.00004362893,0.0007768524,0.001222743,0.0003225471,0.002374899,0.00002545372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870947,0.002431346,0.0005057006,0.0005547223,0.0002098522,0.003361038,0.001446945,0.0001500087,0.004245831],"genre_scores_gemma":[0.9870054,0.001918338,0.001394082,0.001058214,0.0002997307,0.003298929,0.001984284,0.00004372935,0.002997351],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006197758,"threshold_uncertainty_score":0.02073354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01791496854483397,"score_gpt":0.2841616989684662,"score_spread":0.2662467304236322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}